Physician profile
Stuart B Krost
NPI 1831143312
$21,642.94
in general payments reported to CMS, 2019-2025
28 companies · $4,322 in 2025
The $4,322 reported for 2025 was more than what 93% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,340 · 2020: $552 · 2021: $2,665 · 2022: $6,413 · 2023: $2,268 · 2024: $4,084 · 2025: $4,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $27.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,645.20 |
| Travel and Lodging | $27.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,915.02 | 2019-2024 | Proclaim, Eterna |
| Biotronik Nro, INC. | $8,292.64 | 2023-2025 | Prospera, Biotronik |
| Nevro Corp. | $1,091.32 | 2019-2023 | Senza |
| Collegium Pharmaceutical, INC. | $857.78 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $533.49 | 2022-2025 | Relistor, Trulance |
| Protega Pharmaceutials INC | $347.29 | 2022-2025 | Roxybond |
| Valinor Pharma, LLC | $269.77 | 2023-2025 | Movantik |
| Forte Bio-Pharma LLC | $225.33 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Eisai INC. | $188.99 | 2020-2022 | |
| Vertos Medical, INC. | $144.20 | 2021-2024 | Mild Device Kit |
| Pfizer INC. | $144.04 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $91.04 | 2022 | |
| Idorsia Pharmaceuticals US INC | $72.04 | 2022-2024 | Quviviq |
| Redhill Biopharma INC. | $71.74 | 2020-2021 | |
| Zyla Life Sciences, INC. | $54.04 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $39.52 | 2022 | |
| Boston Scientific Corporation | $38.98 | 2022 | |
| Hikma Pharmaceuticals USA | $37.04 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $36.66 | 2022 | |
| Amneal Pharmaceuticals LLC | $30.66 | 2022-2023 | Lyvispah |
| Astrazeneca Pharmaceuticals LP | $25.68 | 2019 | |
| Orexo US, INC. | $24.42 | 2020 | |
| Scilex Pharmaceuticals INC. | $22.90 | 2021 | |
| Kaleo, INC. | $20.63 | 2019 | |
| Masimo Corporation | $20.05 | 2023 | Patient Safetynet System |
| Assertio Therapeutics, INC. | $18.31 | 2019 | |
| Almatica Pharma LLC | $16.56 | 2023 | Gralise |
| Pernix Therapeutics Holdings, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Krost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.